Ayisha Sharma

London

Breaking News Reporters at Endpoints News

NCTJ-qualified health & science journalist 🔬 Breaking news reporter @FT publication @endpointsnews 📰 Bookworm, yogi and proud British-Nepali🇳🇵

Featured in: Favicon

citeline.com (+1) Favicon

informa.com (+3) Favicon

hercampus.com Favicon

clinicaltrialsarena.com Favicon

endpts.com Favicon

newsbreak.com Favicon

invesbrain.com Favicon

fintechreporteruk.com Favicon

theguardian.com Favicon

moneymagpie.com + 6 more

Articles

Sanofi’s Kymab-originated inflammatory drug flunks mid-stage asthma trial

1 week ago | endpts.com | Ayisha Sharma

Sanofi’s efforts to explore its OX40-ligand targeting drug for inflammatory diseases other than eczema have hit a roadblock as the drug failed a Phase 2 …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Merck explores potential of oral peptides in deal with Austrian biotech

1 week ago | endpts.com | Ayisha Sharma

Merck is looking for ways to make its drugs easier to administer. The large pharma is licensing a drug delivery platform from Austrian biotech Cyprumed …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Third Harmonic Bio to shutter; Future Pak once again targets Theratechnologies

1 week ago | endpts.com | Ayisha Sharma

Plus, news about PRISM BioLab and Elix:Third Harmonic Bio to shut down: The San Francisco-based biotechSign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
DHL pours €2B into healthcare logistics; OXB revenues on the rise

2 weeks ago | endpts.com | Ayisha Sharma

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. DHL Group is spending €2 billion … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial

2 weeks ago | endpts.com | Ayisha Sharma

Tempest Therapeutics is mulling its business options, including potential exit pathways, after an inability to raise cash to bankroll its lead cancer asset through a …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Novo Nordisk looks to Brazil to boost GLP-1 manufacturing with $1B+ budget

2 weeks ago | endpts.com | Ayisha Sharma

Novo Nordisk is pouring 6.4 billion Brazilian reais ($1.05 billion) into a factory in Brazil, to ramp up production of its blockbuster GLP-1 drugs after …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis

2 weeks ago | endpts.com | Ayisha Sharma

Cartesian Therapeutics said its autologous CAR-T therapy has shown “sustained benefits” in people with a rare autoimmune disease according to the latest data cut from …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Immunology startup RayThera secures $110M in Series A raise

2 weeks ago | endpts.com | Ayisha Sharma

RayThera has collected $110 million in a Series A raise to help it advance a preclinical pipeline of small molecule drugs for immunological diseases. …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Rhythm touts Phase 3 win for rare obesity drug in people with brain damage

2 weeks ago | endpts.com | Ayisha Sharma

Rhythm Pharmaceuticals is looking to expand the potential market for its rare obesity treatment Imcivree beyond genetic disorders. The company said Monday the medicine reduced … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Painkillers without the addiction? The new wave of non-opioid pain relief

2 weeks ago | theguardian.com | Ayisha Sharma

In January, the US Food and Drug Administration (FDA) approved the first new type of painkiller in more than two decades. The decision roused excitement across the healthcare sector for a key reason: the drug, which is called suzetrigine and sold under the brand name Journavx, is not an opioid. Opioid painkillers such as oxycodone and morphine are still used to treat severe pain in the UK and US. But they come with an obvious downside: the risk of addiction.